Barely Significant
← all excerpts

Author Correction: High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial.

Nat Med · 2026 · PMC13190256 · PMID 42026265

Europe PMCDOI
1
hedged sentence
0.0050
closest p · 0.1× alpha
0.0050
boldest claim

The sentences

nominally significantP = 0.0050actually significant
In the Results, in the “Part B cohort with infantile-onset SMA: neurodegeneration” section, the text “...compared with the ENDEAR matched sham group (30% reduction)” has been corrected to “...compared with the ENDEAR matched sham group (32% reduction)”, and “nominally significant P = 0.0050” has been corrected to “nominally significant P = 0.0075”.

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.